The landscape of drug sensitivity and resistance in sarcoma

By sjmartinez • September 22, 2024

Al Shihabi A, Tebon PJ, Nguyen HTL, Chantharasamee J, Sartini S, Davarifar A, Jensen AY, Diaz-Infante M, Cox H, Gonzalez AE, Norris S, Sperry J, Nakashima J, Tavanaie N, Winata H, Fitz-Gibbon ST, Yamaguchi TN, Jeong JH, Dry S, Singh AS, Chmielowski B, Crompton JG, Kalbasi AK, Eilber FC, Hornicek F, Bernthal NM, Nelson SD, Boutros PC, Federman NC, Yanagawa J, Soragni A. The landscape of drug sensitivity and resistance in sarcoma. Cell Stem Cell. 2024 Sep 17:S1934-5909(24)00296-0. doi: 10.1016/j.stem.2024.08.010. Epub ahead of print. PMID: 39305899.

Tags: Hematology/Oncology, high-throughput drug screening, Organoids, patient-derived models, Precision medicine, Publications, sarcoma, tumor organoids

Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study

Yamamoto K, Bando H, Misumi T, Nishikawa T, Wakabayashi M, Yamazaki K, Maehara Y, Oki E, Saltz LB, Douillard JY, Punt CJ, Koopman M, Van[...]

Transient rapamycin treatment avoids unwanted host immune responses toward AAV-delivered anti-HIV antibodies

Fuchs SP, Mondragon PG, Zabizhin R, Tomer S, Wang L, Cook E, Dudley DM, Weisgrau KL, Furlott J, Coonen J, Alexander E, Xie J, Gao[...]

Lower dose and weekly schedules of selinexor in multiple myeloma – updated evidence on safety and efficacy

Baljevic M, Schiller G, Mark TM, Van Domelen DR, Gasparetto C. Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on[...]